CTNNB1 Antibody

Code CSB-PA00174A0Rb
Size US$299 How to order?
  • Western Blot
    Positive WB detected in: SH-SY5Y whole cell lysate, Hela whole cell lysate
    All lanes: CTNNB1 antibody at 2.5µg/ml
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 86 kDa
    Observed band size: 86 kDa

  • Immunohistochemistry of paraffin-embedded human colon cancer using CSB-PA00174A0Rb at dilution of 1:100

  • IHC image of CSB-PA00174A0Rb diluted at 1:500 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • Immunofluorescence staining of HepG2 cells with CSB-PA00174A0Rb at 1:166, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

  • Immunofluorescence staining of Hela cells with CSB-PA00174A0Rb at 1:166, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

  • Immunoprecipitating CTNNB1 in HT29 whole cell lysate
    Lane 1: Rabbit control IgG instead of CSB-PA00174A0Rb in HT29 whole cell lysate. For western blotting, a HRP-conjugated Protein G antibody was used as the secondary antibody (1/5000)
    Lane 2: CSB-PA00174A0Rb (8µg) + HT29 whole cell lysate (500µg)
    Lane 3: HT29 whole cell lysate (20µg)

  • Immunofluorescence staining of MCF-7 cells with CSB-PA00174A0Rb at 1:166, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) CTNNB1 Polyclonal antibody
Uniprot No. P35222
Target Names CTNNB1
Alternative Names b-catenin antibody; Beta catenin antibody; Beta-catenin antibody; Cadherin associated protein antibody; Catenin (cadherin associated protein); beta 1; 88kDa antibody; Catenin beta 1 antibody; Catenin beta-1 antibody; CATNB antibody; CHBCAT antibody; CTNB1_HUMAN antibody; CTNNB antibody; CTNNB1 antibody; DKFZp686D02253 antibody; FLJ25606 antibody; FLJ37923 antibody; OTTHUMP00000162082 antibody; OTTHUMP00000165222 antibody; OTTHUMP00000165223 antibody; OTTHUMP00000209288 antibody; OTTHUMP00000209289 antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Catenin beta-1 protein (2-781AA)
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated

The CTNNB1 Antibody (Product code: CSB-PA00174A0Rb) is Non-conjugated. For CTNNB1 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA00174B0Rb CTNNB1 Antibody, HRP conjugated ELISA
FITC CSB-PA00174C0Rb CTNNB1 Antibody, FITC conjugated
Biotin CSB-PA00174D0Rb CTNNB1 Antibody, Biotin conjugated ELISA
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA, WB, IHC, IF, IP
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:100-1:500
IF 1:50-1:200
IP 1:200-1:2000
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Immunoprecipitation (IP) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome. In the presence of Wnt ligand, CTNNB1 is not ubiquitinated and accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. Involved in the regulation of cell adhesion, as component of an E-cadherin:catenin adhesion complex. Acts as a negative regulator of centrosome cohesion. Involved in the CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. Blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. Disrupts PML function and PML-NB formation by inhibiting RANBP2-mediated sumoylation of PML. Promotes neurogenesis by maintaining sympathetic neuroblasts within the cell cycle. Involved in chondrocyte differentiation via interaction with SOX9: SOX9-binding competes with the binding sites of TCF/LEF within CTNNB1, thereby inhibiting the Wnt signaling.
Gene References into Functions
  1. CXC chemokine ligand 9 promotes the progression of diffuse large B-cell lymphoma in a beta-catenin-dependent manner. PMID: 30130730
  2. Results suggest that epigenetic regulation of CTNNB1 may serve as a novel avenue to block colon cancer cell migration and invasion. PMID: 29923144
  3. The results demonstrated that 2HF could inhibit EMT, and cell migration and invasion through the Wnt/bcatenin signaling pathway by suppressing GSK3b phosphorylation, betacatenin expression and transactivation. PMID: 30226607
  4. Collectively, these studies suggested the cellular transcription factor beta-catenin stimulates productive herpes simplex virus 1infection, in part because VP16 enhances beta-catenin dependent transcription. PMID: 30077727
  5. CTNNB1 mutations may be more related to tumorigenesis ( aldosterone-producing adenoma) rather than excessive aldosterone production PMID: 28102204
  6. CTNNB1 mutations were found in 60% of Basal cell adenoma but not in basal cell adenocarcinoma. None of the tested cases had PIK3CA mutations. CTNNB1 mutation trended to be more common in those cases having a predominant tubular or tubulotrabecular patterns. PMID: 29224720
  7. Data reveal that post-translational modifications of beta-catenin in the ubiquitin-proteasome pathway yield a truncated beta-catenin molecule containing a serine 552-phosphorylated core region without N and C termini. This proteolytic processing of beta-catenin is required for binding with TCF4 and subsequent transcriptional activation. PMID: 29330435
  8. Results identify CTNNB1 as a Girdin-interacting protein. Girdin-depleted skin cancer cells displayed scattering and impaired E-cadherin-specific cell-cell adhesion. PMID: 30194792
  9. the dysregulation of TET2/E-cadherin/beta-catenin regulatory loop is a critical oncogenic event in HCC progression PMID: 29331390
  10. High CTNNB1 expression is associated with bladder cancer progression. PMID: 30015971
  11. It has been found that miR-27a-3p modulated the Wnt/beta-catenin signaling pathway to promote epithelial-mesenchymal transition in oral squamous carcinoma stem cells by down-regulating SFRP1. PMID: 28425477
  12. Beta-catenin pathway is activated by CBX8 in in hepatocellular carcinoma. PMID: 29066512
  13. our data provide a novel evidence for the biological and clinical significance of SPAG5 as a potential biomarker, and we demonstrate that SPAG5-b-catenin-SCARA5 might be a novel pathway involved in hepatocellular carcinoma progression. PMID: 30249289
  14. Results show that hypoxia enhanced nuclear accumulation and transcriptional activity of beta-catenin which promotes expression of EMT-related genes and eventually contributes to the metastatic process in lung cancer cells. PMID: 30396950
  15. This study demonstrates that FOXC1 induces cancer stem cells (CSCs)-like properties in non-small cell lung cancer (NSCLC) by promoting beta-catenin expression. The findings indicate that FOXC1 is a potential molecular target for anti-CSC-based therapies in NSCLC PMID: 30189871
  16. High TBL1XR1 expression indicates poor disease-free survival of stage I-III colorectal cancer patients; beta-catenin signaling is critical for TBL1XR1-mediated colorectal cancer cells oncogenicity. PMID: 28295012
  17. Taking together, these results suggest that Wnt/beta-catenin signal pathway activation-dependent up-regulation of syncytin-1 contributes to the pro-inflammatory factor TNF-alpha-enhanced fusion between oral squamous cell carcinoma cells and endothelial cells. PMID: 28112190
  18. The disassociation of the beta-catenin/E-cadherin complex in the osteoblast membrane under stretch loading and the subsequent translocation of beta-catenin into the nucleus may be an intrinsic mechanical signal transduction mechanism. PMID: 29901167
  19. Aberrant CTNNB1 expression was seen in a substantial proportion of our hepatocellular carcinoma (HCC) cases. CTNNB1-positive HCC was associated with normal AFP levels, unicentric tumors, well-differentiated histology, and an unfavorable outcome. PMID: 30082549
  20. Long noncoding RNA AFAP1-AS1 enhances cell proliferation and invasion in osteosarcoma through regulating miR-4695-5p/TCF4-beta-catenin signaling. PMID: 29901121
  21. High CTNNB1 expression is associated with the recurrece of Adamantinomatous Craniopharyngiomas. PMID: 29625497
  22. High CTNNB1 expression is associated with uterine fibroids. PMID: 29066531
  23. The nucleus and/or cytoplasm expression of beta-catenin was associated with tumor progression and correlated overall survival of patients with ovarian cancer (OC). beta-catenin may be a possible potential prognostic biomarker for the patients with OC. [review] PMID: 30103006
  24. In the two wild type (WT) cases, two novel alterations were detected: a complex deletion of APC and a pathogenic mutation of LAMTOR2. Focusing on WT DT subtype, deep sequencing of CTNNB1, APC and LAMTOR2 was conducted on a retrospective series of 11 WT DT using a targeted approach PMID: 29901254
  25. DLX1 interacted with beta-catenin and enhanced the interaction between beta-catenin and TCF4 T-cell factor PMID: 29317218
  26. Nuclear beta-catenin immunoreactivity with appropriate criteria may be helpful to distinguish basal cell adenocarcinoma (BCAC) from histologically similar tumors. However, a minor subset of adenoid cystic carcinoma (ACC) with nuclear beta-catenin expression require careful diagnosis. PMID: 29496310
  27. High CTNNB1 expression is associated with metastasis in cholangiocarcinoma. PMID: 30193944
  28. beta;-catenin directly interacts with the Cx43 carboxyl-terminal domain. PMID: 29882937
  29. This study showed that beta-catenin expression was the most evident in the nucleus rather than in cytoplasm. PMID: 29297710
  30. Nuclear beta-catenin accumulation in non-mitotic glioblastoma cells is due to a feed forward mechanism between DOCK4 and beta-catenin. PMID: 28925399
  31. Study found that HIF1alpha overexpression led to an enhanced betacatenin nuclear translocation, while betacatenin silencing inhibited betacatenin nuclear translocation. The enhanced betacatenin nuclear translocation induced resulted in an enhanced cell proliferation and cell invasion, an altered cell cycle distribution, decreased apoptosis, and improved nonhomologous end joining repair under normal and irradiation cond... PMID: 29658569
  32. our results demonstrated that miR-188 inhibits glioma cell proliferation by targeting beta-catenin PMID: 29268818
  33. Marked upregulation of beta-catenin and its downstream targets effectively enhanced hepatosphere formation, with an associated induction of CD133, OCT4 and Sox2 expression and also caused an significant enhancement of HCC proliferation PMID: 29792038
  34. Wnt/beta-catenin signaling pathway may play a significant role in the pathogenesis of preeclampsia by regulating the invasion and proliferation of trophoblast. PMID: 29603045
  35. Associations between environmental variants together with single nucleotide polymorphisms (SNPs) of beta-catenin (ctnnb1) and lung cancer risk were analyzed using a logistic regression model. PMID: 29562493
  36. that CTNNB1 is overexpressed and confers a poor prognosis in acute myeloid leukemia PMID: 29496308
  37. High CTNNB1 expression is associated with cisplatin-resistance in non-small cell lung cancer. PMID: 30009824
  38. beta-catenin immunopositivity is seen in majority of cases of sinonasal sarcoma PMID: 29566950
  39. For the first time, we demonstrated that rather than excluding lymphocytes infiltration as reported in mela-noma, high levels of TILs were associated with beta-catenin overexpression in BC. PMID: 29286921
  40. Study shows that apigenin-induced lysosomal degradation of beta-catenin in Wnt/beta-catenin signaling. PMID: 28337019
  41. Used CRISPR-Cas9 technology to study effect of knockout of catenin beta 1 (CTNNB1) on cell behavior and signal pathways in HEK293 cells. Results showed knockout of CTNNB1 effected Wnt/beta-catenin signaling pathway and suppressed adhesion and proliferation of HEK 293T cells. PMID: 29249062
  42. our results also revealed that lncRNA SNHG20 knockdown inhibited Wnt/b catenin signaling activity by suppressing beta-catenin expression and reversing the downstream target gene expression. Taken together, lncRNA SNHG20 plays an pivotal role in ovarian cancer progression by regulating Wnt/b-catenin signaling PMID: 29101241
  43. Wnt3A regulates the expression of 1,136 genes, of which 662 are upregulated and 474 are downregulated in CCD-18Co cells. A set of genes encoding inhibitors of the Wnt/beta-catenin pathway stand out among those induced by Wnt3A, which suggests that there is a feedback inhibitory mechanism. PMID: 29044515
  44. The aim of our study was to analyze the immunohistochemical expression of beta-catenin, E-cadherin and Snail, depending on clinico-morphological aspects of the laryngeal squamous cell carcinomas. Results revealed variable E-cadherin, beta-catenin and Snail expression, depending on differentiation degree and tumor stage. PMID: 29250652
  45. In this study we showed that the activation of Wnt/beta-catenin pathway culminates in the upregulation of MGAT1 enzyme both at transcriptional and post-transcriptional levels. We also showed that overexpression of the beta-catenin gene (CTNNB1) increased the promoter activity of MGAT1. PMID: 29310626
  46. CTNNB1 mutation is associated with acquired resistance to KIT inhibitor in metastatic melanoma. PMID: 28421416
  47. three CTNNB1 SNPs were suggested to have the potential to be novel biomarkers for risk prediction of cancer in overall population or some specific subgroups. [Review] PMID: 28963373
  48. A CTNNB1 exon 3 mutation restricted to the areas exhibiting both positive glutamine synthetase (GS) and C-reactive protein (CRP) expression, whereas wild-type CTNNB1 was found in areas showing only CRP staining. These two cases illustrate focal beta-catenin activation that can occur within Inflammatory hepatocellular adenoma (IHCAs). PMID: 28618047
  49. Results show that E-cadherin/beta-catenin complex is disrupted by ICAT promoting epithelial-mesenchymal transition of cervical cancer cells. PMID: 29048651
  50. Toosendanin administration inhibited growth and liver metastasis of orthotopically implanted SGC7901 tumors in vivo through miR200amediated beta-catenin pathway. Our data suggest that Toosendanin may suppress oncogenic phenotypes of human GC cells partly via miR200a/beta-catenin axis. Hence, Toosendanin may have a promising chemotherapeutic activity for GC therapy. PMID: 29048657

Show More

Hide All

Involvement in disease Colorectal cancer (CRC); Pilomatrixoma (PTR); Medulloblastoma (MDB); Ovarian cancer (OC); Mesothelioma, malignant (MESOM); Mental retardation, autosomal dominant 19 (MRD19); Vitreoretinopathy, exudative 7 (EVR7)
Subcellular Location Cytoplasm. Nucleus. Cytoplasm, cytoskeleton. Cell junction, adherens junction. Cell junction. Cell membrane. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle pole. Cell junction, synapse. Cytoplasm, cytoskeleton, cilium basal body.
Protein Families Beta-catenin family
Tissue Specificity Expressed in several hair follicle cell types: basal and peripheral matrix cells, and cells of the outer and inner root sheaths. Expressed in colon. Present in cortical neurons (at protein level). Expressed in breast cancer tissues (at protein level).
Database Links

HGNC: 2514

OMIM: 114500

KEGG: hsa:1499

STRING: 9606.ENSP00000344456

UniGene: Hs.476018

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1